Clinical study of mosapride citrate combined with bifidobacterium quadruple in irritable bowel syndrome
Objective:To investigate the efficacy and safety of the combination of mosapride citrate and bifidobacterium quadruple viable bacteria in treating irritable bowel syndrome.Method:A total of 79 patients with irritable bowel syndrome admitted to the Department of Gastroenterology of our hospital from January 2021 to December 2023 were randomly divided into a control group(n=40)and a study group(n=39).The control group was treated with oral administration of mosapride citrate tablets 5 mg,3 times·day-1,and the study group was treated with oral administration of bifidobacterium quadruple viable bacteria 1.5 g,3 times·day-1 on this basis.After 1 month of treatment,the clinical efficacy of the two groups was compared according to the efficacy evaluation criteria.Before and after treatment,D-lactic acid(D-LA)and endotoxin(ET)were measured by the dry chemistry method,and diamine oxidase(DAO)was measured by the dynamic turbidity method.Bifidobacteria,lactobacilli,and enterobacteria were detected by colony culture,and adverse reactions during the medication period were observed.Results:The clinical efficacy of the study group was significantly higher than that of the control group(P<0.05).After treatment,the levels of bifidobacteria and lactobacilli in both groups significantly increased compared with those before treatment,while the levels of enterobacteria significantly decreased compared with those before treatment.The levels of bifidobacteria and lactobacilli in the study group were significantly higher than those in the control group,and the levels of enterobacteria were lower than those in the control group(P<0.05).After treatment,the D-LA,ET,and DAO levels in both groups were lower than those before treatment,and the D-LA,ET,and DAO levels in the study group were significantly lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combined use of mosapride citrate and bifidobacterium quadruple can enhance the effectiveness of treating irritable bowel syndrome,and improving intestinal flora and intestinal mucosal barrier function.
NETL
NSTL
万方数据
